Compare Amgen, Inc. (AMGN) vs US Bancorp (USB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs US Bancorp — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while US Bancorp trades at $62.41 (market cap $97.22B). The key difference: Amgen, Inc. is far larger — about 2× US Bancorp's market cap, and US Bancorp pays the higher dividend (3.33%). Which is the better fit depends on your goals.
| AMGN | USB | |
|---|---|---|
Market Cap | $196.12B | $97.22B |
Sector | Health | Financials |
52-Week High | $388.16 | $62.89 |
52-Week Low | $271.18 | $43.94 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
U.S. Bancorp (USB) trades at $62.41, up 0.82% with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with three consecutive quarterly earnings beats, a P/E of 13.08, and net income margin of 27.04%. Recent developments include the launch of Enhanced Payments for small businesses and a planned dividend increase following successful stress test results.
The outlook remains positive with analyst consensus targeting $67.00 (7.4% upside). Key opportunities include sustained earnings growth and dividend reliability, while risks involve negative cash flow trends and rising debt-to-asset ratios. The stock presents a balanced risk-reward profile for value-oriented investors seeking financial sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
